Breathe Right nasal strips,
does it really help with Improved sleep quality in people with chronic nocturnal nasal congestion?
research showsThe grade is D with 28 points. In two GSK trials of 140 and 130 participants, the co-primary NRQLQ Sleep Problems domain and morning tired-unrefreshed item were no better than placebo at days 7 or 14. The trials had separate registrations but shared authors, sponsor, timing, and protocol structure, so they were not inflated into independent repeated refutation.
ads claimMechanically pulling the external nose open can enlarge the passage, but that is a different claim from improving sleep quality. The primary patient-reported sleep outcomes were not better than placebo.
Useful facts when choosing a product
- The active device was an asymmetric butterfly external nasal dilator; placebo had matching appearance without functional spring force.
- Both trials used the strip for about eight hours nightly over 14 days.
- PMID 31485980 is a correction notice, not a new clinical study.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.breathe-right-external-nasal-dilator-strips.intranasal.sleep-quality-with-chronic-nocturnal-nasal-congestion.improve.placeboUnknown > Breathe Right external nasal dilator strips > Intranasal > sleep quality with chronic nocturnal nasal congestion > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Two two-site US trials compared the strip with a visually matched nonspring placebo for 14 days. Study 1 analyzed all 140 randomized participants by intention to treat; Study 2 analyzed 128 of 130. Dispensing staff allocated treatment from a sponsor-provided schedule, while other personnel able to influence outcomes were masked. Both trials finished in 2010-2011 but were registered in 2018, each enrolled fewer than 200 people, and chronic sleep problems were assessed for only 14 days. Both were funded by GSK Consumer Healthcare, and two authors were GSK employees. PMID 31485980 is an open-access correction to the article, not a separate trial.
Why this is classified as D (28)
Co-primary sleep outcomes were null across the same GSK development program, but exact intervals and a clinical boundary were unavailable, giving D with 28 points rather than independent repeated refutation.
Counterpoint. Temporary nasal-opening or easier-breathing effects are separate outcomes and are not denied by this sleep-quality verdict.
Rejudgment record. Cross-check applied — Cross-checked the article with NCT03549117 and NCT03549130 for co-primary outcomes, intention-to-treat denominators, allocation and masking, retrospective registration, shared sponsorship, and the correction notice
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E0 | Null |
| Precision | CX | No pooled confidence interval could be confirmed |
Stored derived and displayed grades match; this is not a current recalculation or validity check (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Breathe Right improves sleep quality in nocturnal congestion | D | All eight co-primary comparisons across two trials were null. |
| Breathe Right mechanically dilates the external nose | ? | This physical action is separate from the sleep-quality efficacy grade. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Noss MJ, Ciesla R, Shanga G. 2019 Study 1 | Two-site randomized double-blind placebo-strip-controlled trial | 140 randomized and all 140 in intention-to-treat analysis (70/70) | Sole sponsorship by GlaxoSmithKline Consumer Healthcare | NRQLQ Sleep Problems and morning tired-unrefreshed item at days 7 and 14 | All four co-primary between-group comparisons had P>0.05 | First null trial in the same manufacturer development program |
| Noss MJ, Ciesla R, Shanga G. 2019 Study 2 | Two-site randomized double-blind placebo-strip-controlled trial | 130 randomized; 128 in intention-to-treat analysis (64/64) | Sole sponsorship by GlaxoSmithKline Consumer Healthcare | NRQLQ Sleep Problems and morning tired-unrefreshed item at days 7 and 14 | All four co-primary between-group comparisons had P>0.05 | Second null trial sharing authors, sponsor, timing, and protocol structure within the same program |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-15).
Final verification and publication gate: Codex · Evidence date: 2026-08-15 · Corrections: none
Cite this verdict
[Chamgap] Breathe Right nasal strips x sleep quality with nocturnal congestion — Evidence Grade D·28. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/breathe-right-nasal-strips-nocturnal-congestion-sleep-quality/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.